- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
Bavarian Nordic
Market Cap: DKK 14.0b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 185.60
7D
5.2%
1Y
-21.9%
H. Lundbeck
Market Cap: DKK 40.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 42.52
7D
2.3%
1Y
8.9%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 294.70
7D
-3.4%
1Y
-9.6%
H. Lundbeck
Market Cap: DKK 40.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 35.90
7D
1.0%
1Y
10.0%
Gubra
Market Cap: DKK 6.2b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 371.80
7D
2.5%
1Y
5.3%
Genmab
Market Cap: DKK 120.9b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 2,027.00
7D
1.4%
1Y
35.4%